URSULA CABAUATAN: Open Payments
NPI 1245814136 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$643 in 23 payments from 13 companies in 2025. Trend: 2023 $532 · 2024 $1,454 · 2025 $643
Food & beverage: $544Education: $99
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 6 | $197 |
| Daiichi Sankyo Inc. | 2 | $124 |
| Janssen Biotech, Inc. | 3 | $61 |
| Syndax Pharmaceuticals, Inc. | 2 | $60 |
| Eisai Inc. | 2 | $33 |
| Lilly USA, LLC | 1 | $32 |
| Stemline Therapeutics Inc. | 1 | $24 |
| Genmab U.S., Inc. | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $20 |
| TAIHO ONCOLOGY, INC. | 1 | $19 |
Products named: Trodelvy, Enhertu, ERLEADA, Lenvima, VERZENIO, Orserdu, Epkinly, DANZITEN.
Industry payments across TX — which companies pay providers there.
